Pharmacological Management of Hypertension

Pharmacological management of hypertension centres on modulating key pathways that govern vascular tone, fluid balance and cardiac output. First-line agents include inhibitors of the renin–angiotensin–aldosterone system (RAAS) such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which reduce vasoconstriction and sodium retention. Calcium channel blockers promote arterial dilation by preventing calcium influx into vascular smooth muscle, while diuretics enhance renal sodium and water excretion to lower blood volume. Beta-adrenoceptor antagonists decrease heart rate and myocardial contractility, further reducing blood pressure. Combination therapies often yield synergistic benefits, allowing lower doses of each agent and mitigating adverse effects. Emerging strategies seek to refine these approaches through precision targeting of hormonal and metabolic axes, minimising off-target toxicity. Practical applications span global health settings, from resource-limited clinics deploying low-cost generics to advanced centres integrating digital monitoring for dose titration. Consistent evidence confirms that optimal pharmacotherapy can substantially reduce the incidence of stroke, myocardial infarction and renal disease, underscoring its central role in public health.

Research from Nature Portfolio

Recent studies have demonstrated that next-generation non-peptide antagonists of mineralocorticoid receptors achieve highly selective blockade of aldosterone-driven signalling. In preclinical models, these compounds substantially attenuated vascular remodelling and inflammation without the hyperkalaemia commonly observed with earlier therapies. Early-phase human trials report significant reductions in systolic pressure in patients with resistant hypertension, suggesting a promising avenue for individuals unresponsive to conventional RAAS inhibitors.

Investigations into sodium-glucose co-transporter 2 (SGLT2) inhibitors have revealed sustained antihypertensive effects in non-diabetic cohorts. Mechanistic analyses attribute this benefit to enhanced natriuresis, reduced arterial stiffness and improved endothelial function. Integration of SGLT2 inhibitors into combination regimens has shown additive blood pressure lowering when paired with ACE inhibitors, offering a novel adjunctive strategy that leverages metabolic pathways to complement established vascular targets.

Pharmacological Management of Hypertension publication trend

The graph below shows the total number of articles in pharmacological management of hypertension across all publications each year (not limited to Nature Index journals).

Technical terms

Renin–angiotensin–aldosterone system (RAAS): A hormone cascade regulating vascular tone and fluid balance, often targeted in hypertension treatment.

Sodium-glucose co-transporter 2 (SGLT2): A renal transporter involved in glucose reabsorption, whose inhibition can inadvertently reduce blood pressure.

Mineralocorticoid receptor antagonist: A class of drugs that block aldosterone effects, reducing sodium retention and vascular remodelling.

Alpha- and beta-adrenoceptor antagonists: Agents that respectively block α- or β-adrenergic receptors, decreasing peripheral resistance and cardiac output.

References

1. The use of intravenous labetalol in the setting of rapid atrial fibrillation secondary to methamphetamine use. Toxicology Communications (2019).
2. Treatment of Severe Hypertension with Peroral Labetalol. Upsala Journal of Medical Sciences (1987).